anti-BCR CAR T-cell therapy (Xenetic Biosciences)

N/A

Report date: 2025/01/26 19:31:59

Base Information

Drug Nameanti-BCR CAR T-cell therapy (Xenetic Biosciences)
Drug Alias NameXCART CAR T therapy (Xenetic Biosciences)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionBcr-Abl tyrosine kinase modulators
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEastern EuropeUnited StatesRussian Federation +[5] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXenetic Biosciences (Uk) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXenetic Biosciences (Uk) Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A